Aclaris Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis did not achieve its primary endpoint, while also announcing the initiation of a new Phase 2b trial and additional …
Rezolute, Inc. filed a Form 8-K with the SEC on November 16, 2026, disclosing an underwriting agreement dated November 13, 2026, covering an underwritten public offering of common stock and pre-funded warrants expected to generate approximately $93.5 million in net proceeds.
Oscar Health, Inc. filed a Form 8-K on November 16, 2026, disclosing the appointment of three new independent directors to its Board of Directors, effective November 13, 2026, expanding the board from eight to eleven members.
Henry Schein, Inc. filed a Form 8-K on November 16, 2026, disclosing a voluntary change to its non-GAAP financial measure presentation and a corresponding update to its full-year 2026 non-GAAP diluted earnings per share guidance.
Lithium Americas Corp. filed a current report on November 16, 2026, disclosing that on November 10, 2026, it entered into Omnibus Waiver, Consent and Amendment No. 3 with the U.S. Department of Energy and other parties, amending key agreements governing the DOE loan for …
OZ Vision Inc. filed a current report on November 16, 2026, disclosing that its Board of Directors concluded investors should no longer rely on the company's previously issued audited financial statements for the fiscal years ended June 30, 2025 and June 30, 2026, due …
Summit Therapeutics Inc. filed a Form 8-K on November 16, 2026, disclosing that the U.S. Food and Drug Administration issued a Complete Response Letter on November 15, 2026, regarding the Biologics License Application for ivonescimab in combination with platinum-containing chemotherapy for certain non-small cell …
Zymeworks Inc. filed an 8-K on November 16, 2026, disclosing that its Board of Directors authorized a second 2026 share repurchase program allowing the company to repurchase up to $200.0 million of its outstanding common stock through 2028.
Quality Industrial Corp. filed a Form 8-K on November 16, 2026, announcing the release of its financial results for the three and nine months ended September 30, 2026, alongside the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, …
XTI Aerospace, Inc. filed a Form 8-K on November 16, 2026, disclosing that Chief Operating Officer Michael A. Tapp resigned from his position effective immediately on November 9, 2026.